SCM
ADCT icon

Silverarc Capital Management’s ADC Therapeutics ADCT Stock Holding History

Silverarc Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,795,080
Closed -$5.65M – 62
2024
Q3 		$5.65M Buy
1,795,080
+26,310
+1% +$83K 1.27% 26
2024
Q2 		$5.59M Buy
1,768,770
+1,267,548
+253% +$5.04M 1.32% 26
2024
Q1 		$2.25M Buy
+501,222
New +$1.85M 0.63% 47

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silverarc Capital Management's ADCT Position: Q4 2024 in Review

Silverarc Capital Management sold out of ADC Therapeutics (ADCT) in Q4 2024, closing a stake of 1,795,080 shares — an estimated $5.65M sold.

Silverarc Capital Management first reported a position in ADCT in Q1 2024 and held it in 3 quarters. The position peaked at $5.65M in Q3 2024. 83 funds tracked by Wall St. Rank hold ADCT as of Q4 2024.

  • Silverarc Capital Management reported no remaining ADC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 1,795,080 ADC Therapeutics shares in Q4 2024, an estimated $5.65M.
  • Silverarc Capital Management first reported a position in ADC Therapeutics in Q1 2024 and held it in 3 quarters.
  • Silverarc Capital Management's ADC Therapeutics position peaked at $5.65M in Q3 2024.
  • 83 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.